case_images: PMC10400294_01
case_images: MR image of the liver lesion prior to third-line GTX therapy.
case_images: CRIONM2023-8751205.001.jpg
case_images: PMC10400294_01_CRIONM2023-8751205.001.jpg
case_images: fig1
case_images: FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) in the second line starting in April 2020. Five months later, imaging demonstrated progression (Figure 1).